Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments
- 14 November 2006
- journal article
- review article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 14 (2) , 942-953
- https://doi.org/10.1245/s10434-006-9227-1
Abstract
Small molecule tyrosine kinase inhibitors (TKIs) are developed to block intracellular signaling pathways in tumor cells, leading to deregulation of key cell functions such as proliferation and...Keywords
This publication has 103 references indexed in Scilit:
- Phase II Study of Erlotinib in Patients With Advanced Biliary CancerJournal of Clinical Oncology, 2006
- Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancerBritish Journal of Cancer, 2006
- Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancerBritish Journal of Cancer, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002